HPV Oncogenes rewire DNA crosslink repair to create a PRIMPOL-dependent therapeutic vulnerability
Cisplatin-based chemoradiation is the standard of care for both HPV-negative (HPV-) and HPV-positive (HPV+) head and neck squamous cell carcinoma (HNSCC), even though patients with HPV+ tumors have better treatment responses and a better prognosis. Understanding how HPV status shapes this response could guide alternative strategies that lower long-term toxicity. Using genome-wide CRISPR screens,…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
